In this prospective, multicentre, response-adapted study of HER2-positive breast cancer, we observed that patients who were non-responders to trastuzumab-based neoadjuvant therapy, as determined by breast MRI after two cycles of treatment, had a significantly lower tpCR rate compared to those who showed early response. This evidence concerns the gene ERBB2 and breast cancer.